HIV and Pregnancy: A Short Review

Sofoudis C*

2nd Department of Obstetrics and Gynecology University of Athens, Aretaieion Hospital, Greece

Abstract

The incidence and existence of human immunodeficiency virus concerning women of reproductive age continues to increase globally. The care of HIV-infected women is not simple and must be focused on including the current and future health of these women, the minimization of the risk of maternal–infant transmission and the maintenance of the well-being of the fetus and neonate. Many maternal and obstetrical factors can affect the vertical transmission. The answer to this problem is the optimal medical and obstetrical care.

Keywords: Pregnancy; HIV; Vertical transmission

Introduction

The human immunodeficiency virus continues to be expanded around the world causing an estimated 16,000 new infections per day [1]. 2.1 million women and 590,000 children below age of 15 were newly infected through their mothers before or during birth or through breastfeeding [1].

Perinatal transmission accounts around >90% of HIV infections in infants and children and is responsible for almost new HIV infections in preadolescent children. Perinatal transmission is also responsible for >90% of pediatric AIDS in the United States [2]. The possible mechanisms which are responsible for vertical transmission might be the transplacental microtransfusions of maternal blood into the fetal circulation during contractions, labor and separation of the placenta before clamping of the umbilical cord [3], the ascending infection through the cervix after rupture of the amniotic membranes, which affects the amniotic fluid and the absorption of the virus through the infant’s immature digestive tract. A pregnancy in an HIV-infected woman is considered a high-risk pregnancy. National guidelines according the deal of HIV-infected women propose intensive ultrasound screening. In case of fetal anomaly, invasive prenatal testing can be offered [4]. The infections’ rate which is presented during pregnancy indicates the stage of HIV disease and degree of immunosuppression. Pneumocystis carinii pneumonia appears with more severe clinical symptoms [5].

Furthermore, there are reports concerning HIV associated infections such as candidiasis and urinary tract infections presented with more severe clinical symptoms during pregnancy. Many obstetrical complications can occur in HIV-infected pregnant women. Delivery before the 37th week of gestation is correlated with increased HIV transmission rate [6]. Low birth weight (<than 2500 g) is presented as a co-factor associated with vertical transmission and reflects the rate of intrauterine infection. Additionally, it reflects the placenta insufficiency or severe HIV infection.

In developed countries, with access to medical opportunities, HIV infection is not associated with maternal mortality or morbidity. On the contrary, in many countries in Africa, HIV infection plays a significant role in maternal mortality [7]. HIV-infection during pregnancy is associated with other viral diseases such as influenza and varizella, in which the host response is largely cell mediated [8].

The incidence of HIV infection in the United States varies from 40,000 to 56,300 annually [9,10]. Around 25% of HIV infected persons do not know their medical condition [11]. The biological interaction between HIV and pregnancy is not well understood globally. It has been said that pregnancy can increase the HIV presence, because of the correlation between its presence and the immunosuppression [12,13]. There are many pathological connections which can clear out this correlation. To begin with, we must give a great attention to the compromised immune status and general poor health of HIV-infected women which allow them to become more vulnerable to infections and mostly to puerperal sepsis [14]. Additionally, HIV related thrombocytopenia may lead to increased risk of hemorrhage. Moreover, social factors can be exacerbated in HIV-infected women because of the discrimination, the stigma and the social isolation facing every day as members of a society [15].

Discussion

According to the World Health Organization (WHO) an estimated 15, 7 million women and 2, 1 million children under the age of 15 living with AIDS [16]. Generally, the main focus on the management of pregnant women with HIV infection still remains the continuance of the antiretroviral therapy during the pregnancy regardless of viral load and CD4 cell in order to minimize the mother-to-child transmission [17-19]. In 2006, the World Health Organization (WHO) guidelines proposed relevant agents concerning triple therapy, focusing on decreased rates of mother-to-child transmission (MTCT) than monotherapy one [18,19].

Globally, combination of zidovudine/lamivudine with a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a Proteasome Inhibitor (PI) is the gold standard as far as HIV infected pregnant women regards. On the contrary, HIV-infected women with intolerance to zidovudine because of low count of red plattes or resistance to drugs, they are able to use another drug method.

During pregnancy, when the CD4 lumphocytes status decreases to <250 cells/mm³, the optimal choice would be nevirapine. There are several cases reported with developed fatal rash and liver toxicity [20].

The principle use of antiretroviral therapy represents the cornerstone concerning HIV-infected women, not only for their own treatment but also for mother-to-child transmission (MTCT). Taking into consideration and starting an antiretroviral therapy to HIV-infected women is not simple and must be focused on including the current and future health of these women, the minimization of the risk of maternal–infant transmission and the maintenance of the well-being of the fetus and neonate. Many maternal and obstetrical factors can affect the vertical transmission. The answer to this problem is the optimal medical and obstetrical care.

*Corresponding author: Sofoudis C, 2nd Department of Obstetrics and Gynecology University of Athens, Aretaieion Hospital, Ippokratous 209 , 11472 Athens, Greece, Tel: 6943662013; E-mail: chrisostomos.sofoudis@gmail.com

Received September 01, 2014; Accepted October 29, 2014; Published October 31, 2014

Citation: Sofoudis C (2014) HIV and Pregnancy: A Short Review. J Clin Case Rep 4: 436. doi:10.4172/2165-7920.1000436

Copyright: © 2014 Sofoudis C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
infected pregnant women, we should focus on the offering data from the antiretroviral drugs. Deriving from the global literature, the number of the HIV-infected pregnant women under antiretroviral therapy has dramatically increased and our concern must be on the possible side-effects which can be the reason for early miscarriage, mainly during the first trimester. This period of time is vulnerable to teratogenetic effects because of the completion of the organogenesis [21,22].

The classification of congenital abnormalities is based on WHO criteria and contains any major formed abnormality, or any combination of two or more abnormalities, developing in fetuses below the 20th week of gestation. The most significant abnormalities are the following: polydactylism, malformed ear, abnormalities in the feet, minor mouth abnormalities, undescended testes, accessory nipple, spinal hair patch, strawberry nevi, skin tag, and subependymal cysts [23].

There is a strong belief that a positive HIV infected woman should perform a full physical examination even on her first medical appointment to her physician. A Pap-smear should be performed if the woman has not a recent one. Colposcopy must be performed in all cases of atypical Pap smear.

According to the recent bibliography, it is suggested that elective caesarian section can decrease the mother-to-child transmissions rate [24]. This form of delivery can cause maternal complications and deals with great postoperative morbidity [25]. Prophylactic antibiotic seems to be necessary during the time of delivery. It must be given great attention to postpartum complications such as infections from urinary tract and episiotomy. Follow up care and methods of contraception are mandatory for these women.

Conclusion

It is well known that a rapidly increase of number of HIV-infected pregnant women should be mentioned. The main medical goal remains the primary detection of acute HIV infection and the rapidly diagnosis of clinical symptoms. Great attention must be given to mother to child transmission and to postpartum care. More research must be conducted in order to improve the time line of HIV infection from first exposure to development of anti-HIV-1 antibodies and the implications concerning the early detection.

References

1. The UNAIDS/WHO Working Group on global HIV/AIDS and STI Surveillance.
2. Minkoff H (2003) Human immunodeficiency virus infection in pregnancy. Obstet Gynecol 97:179-179.
3. Lin HH, Kao JH, Hsu HY, Mizokami M, Hirano K, et al. (1996) Least microtransfusion from mother to fetus in elective cesarean delivery. Obstet Gynecol 87: 244-248.
4. Mandelbrot L, Jasseron C, Eloukou (2009) Amniocentesis and mother-to-child human immunodeficiency virus transmission in the National Agency for Research on AIDS and Viral Hepatitis the French Perinatal Cohort. Am J Obstet Gynecol 200: 60.
5. Minkoff H, deRegt RH, Landesman S, Schwarz R (1986) Pneumocystis carinii pneumonia associated with acquired immunodeficiency syndrome in pregnancy: a report of three maternal deaths: a report of three maternal deaths. Obstet Gynecol 2: 284-287.
6. Minkoff H, Mofenson LM (1994) The role of obstetric interventions in the prevention of pediatric human immunodeficiency virus infection. Am J Obstet Gynecol 7: 67-75.
7. Lewis G (2004) Beyond the numbers: reviewing maternal deaths and complications to make pregnancy safer. Geneva: World Health Organization 77-102.
8. Nanda D, Minkoff HL (1989) HIV in pregnancy—transmission and immune effects. Clin Obstet Gynecol 32: 456-466.
9. Center for Disease Control and Prevention (2007) HIV/AIDS Surveillance Report. Department of Health and Human Services, Centers for Disease Control and Prevention 19: 2-62.
10. Hall HI, Song R, Rhodes P, Prejean J, An Q, et al. (2008) Estimation of HIV incidence in the United States. JAMA 300: 520-529.
11. Marks G, Crepaz N, Janssen RS (2006) Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 20: 447-450.
12. Lindgren S, Martin C, Anzén B, Strand H, Bredberg-Rädin U, et al. (1996) Pattern of HIV viremia and CD4 levels in relation to pregnancy in HIV-infected women. Scand J Infect Dis 29: 425-433.
13. Rich KC, Siegel JD, Jennings C, Rydman RJ, Landay AL (1995) CD4+ lymphocytes in perinatal human immunodeficiency virus (HIV) infection: evidence for pregnancy-induced immune depression in uninfected and HIV-infected women. J Infect Dis 72: 225-227.
14. Graham W, Hussein J (2003) Measuring and estimating maternal mortality in the era of HIV/AIDS. Workshop on HIV/AIDS and Adult mortality in developing countries. New York: Population Division, USA.
15. http://aidsinfo.nih.gov/contentfiles/ivguidelines/perinatalgl.pdf.
16. Coll O, Fiore S, Florida M, Giaquinto C, Grosch-Wormer I, et al. (2002) Pregnancy and HIV infection: A European consensus on management. AIDS 2: 51-58.
17. Burdge DR, Money DM, Forbes JC, Waimslay SL, Small F, et al. (2003) Canadian consensus guidelines for the management of pregnancy, labour and delivery and for postpartum care in HIV-positive pregnant women and their offspring (summary of 2002 guidelines). CMAJ 68: 67-674.
18. http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf.
19. Ome Gillmann J, Becquet R, Eloueui DK, Leroy V, Perez F, et al. (2008) Children and HIV/AIDS: from research to policy and action in resource limited settings. AIDS 22: 797-805.
20. Panel on Treatment of HIV infected pregnant women and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal transmission in the United States.
21. Mirochnick M, Best BM, Clarke DF (2010) Antiretroviral pharmacology: special issues regarding pregnant women and neonates. Clin Perinatal 37: 997-1027.
22. Newscaffer CJ, Corroft J, Anderson CE, Hauck WW, Tumer BJ (2000) Perinatal zidovudine use and congenital anomalies in a Medicaid population. J Acquir Immune Defic Syndr 24: 249-256.
23. Correa Villasenor A, Gragan J, Kucik J, O’Leary L, Siffel C, et al. (2003) The Metropolitan Atlanta Congenital Defects Program: 35 years of birth defects surveillance at the Centers for Disease Control and Prevention. Birth Defects Res A Clin Mol Teratol 67: 617-624.
24. Peckham C, Newell ML (1997) Human immunodeficiency Virus infection and mode of delivery. Acta Paediatractica 86: 421-104-106.
25. Semprini AE, Castagna C, Ravizza M (1995) The incidence of complications after caesarian section in 156 HIV positive women. AIDS 9: 913-917.